Home

WESEEYOU

Intercept’s commitment to research is a commitment to you

The advances we are making in the development of novel treatments for liver diseases such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) have the potential to change the lives of patients and physicians who currently have few, if any, therapeutic options.

LEARN ABOUT PBC AND NASH >

News

Tuesday, July 21, 2015

Intercept Pharmaceuticals Appoints Richard Kim as Senior Vice President, Commercial Head of U.S.
See the press release >

You are now being redirected to Intercept’s job application site, hosted by Pereless Systems.